Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2014

View Archived Issues

Gilead Sciences begins phase Ib study of GS-9883

Intra-Cellular Therapies and Takeda terminate collaboration to develop PDE1 inhibitors

Single nucleotide mutation in NFIA gene leads to brain malformation and urinary tract defect

Eisai advances pipeline in second quarter of fiscal 2014

Chemically attenuated whole parasite blood-stage malaria vaccine approach tested in humans

IntelGenx completes pilot study of INT-0036 for schizophrenia

Protection against T. cruzi observed with ArtinM in an acute experimental infection model

Affinivax launched with funding from Bill & Melinda Gates Foundation

Altor BioScience begins development of ALT-803 for multiple myeloma

Asana BioSciences reports discovery of kinase inhibitors for cancer

OncoArendi Therapeutics discloses new cancer treatments

Sage Therapeutics synthesizes novel GABA(A) receptor modulators

Amgen reports topline secondary endpoint results from TRINOVA-1 trial

D-Pharm reports data from phase II study of THR-18 in stroke patients treated with tPA

Ruga Corp. patents new B-raf kinase inhibitors

Chinese researchers prepare and test MKK1 inhibitors

Bayer completes acquisition of Dihon Pharmaceutical Group

NicOx reports development of NO donors

Repurposing of an approved glaucoma drug for the treatment of type 2 diabetes

CXCL10 gene polymorphism associated with malaria susceptibility in Ghanaian children

MedImmune to acquire tissue biomarker analysis company

EMA accepts Oleogel-S10 MAA for review

Terumo applies for approval of skeletal myoblast sheets

Kancera selects first candidate in ROR project

USAMRIID demonstrates in vitro activity of two HemispheRx drugs against Ebola virus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...